The latest prices for a box of different versions of Amivantamab are announced

Introduction: Amivantamab monotherapy is a treatment option for adult patients with advanced NSCLC with activating EGFR exon 20 insertion mutations after failure of platinum drug therapy. Evantumumab is an innovative bispecific antibody drug that produces significant inhibitory effects on specific types of tumor cells through its unique bispecific binding ability and signal transduction blocking mechanism, as well as the destructive effect mediated by immune effector cells.

The latest prices for a box of different versions of Amivantamab are announced

Currently, we know that there is only one version of , and it is the original drug version, which is relatively expensive. Evantumumab produced by Janssen Pharmaceuticals in the United States is an original research drug. The specification of a box is 350mg/7ml/bottle, and the price of a box is about 10,300$-10,900$. Patients need to pay for it at their own expense and cannot be reimbursed by medical insurance.

The above prices are for reference only. If you need the latest information, it is recommended to consult the local medical institution or drug supplier for clarification. After purchasing evantumumab, you should understand the medication, precautions and other medication information for special groups.

Special population use of evantumumab

1. Lactating women: evantumumab may be passed to the baby through breast milk, which may have adverse effects on the baby. Breastfeeding women should suspend breastfeeding during evantumumab treatment and for 3 months after the end of final treatment to ensure the safety of the infant.

2. Pediatric patients: The therapeutic effect of evantumumab in pediatric patients has not been fully verified, so its use in pediatric patients should be cautious.

3. Elderly patients: Elderly patients need to pay special attention when receiving evantumumab treatment, and should be under the close guidance and supervision of medical professionals to ensure the safety and effectiveness of the treatment.

Effectiveness of evantuzumab

In a multicenter, open-label trial, 308 patients with locally advanced or metastatic NSCLC harboring EGFR exon 20 mutations were randomized in a 1:1 ratio to receive evantuzumab combined with carboplatin and pemetrexed or carboplatin and pemetrexed. The primary efficacy outcome measure is progression-free survival (PFS), and the key secondary outcome measure is overall survival (OS).

The analysis showed that the median PFS was 11.4 months in the evantumumab group and 6.7 months in the carboplatin group. The OS results were not yet mature, but the final analysis reported a prespecified mortality rate of 44%, indicating that there was no adverse trend.